Vical Incorporated and Brickell Biotech Inc. announced a definitive merger agreement under which Brickell would merge with a wholly owned subsidiary of Vical in an all-stock transaction.
Syneos Health, the only fully integrated biopharmaceutical solutions organization, announced the appointment of Patrick Nealon as Executive Vice President and General Manager of Oncology Clinical Development.
New interim data from the ongoing open-label, pivotal EVOLVE-MS-1 study indicate that Biogen’s investigational treatment diroximel fumarate was generally well tolerated in people with relapsing MS.
B. Braun Announces $1 Billion Investment to Alleviate IV Fluid Shortages in the U.S. Healthcare System
B. Braun Medical Inc. announced Solutions for Life, a $1 billion investment in new and enhanced IV therapy manufacturing facilities to help ensure a reliable and consistent supply of vital IV fluids that American health care providers need every day.
Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma
Cellectar Biosciences Inc. announced that the U.S. Food and Drug Administration granted Fast Track Designation for CLR 131 in fourth line or later relapse/refractory multiple myeloma.
Clinical-stage immuno-oncology company Forty Seven Inc. announced a collaboration with Acerta Pharma, AstraZeneca’s hematology research and development center of excellence.
The European Commission approved Dupixent (dupilumab) for use in adults and adolescents 12 years and older as an add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide, who are inadequately controlled with high dose inhaled corticosteroid plus another medicinal product for maintenance treatment.
Akcea Therapeutics Inc. and Ionis Pharmaceuticals Inc. announced that Waylivra received conditional marketing authorization from the European Commission as the only therapy for FCS.
The acquisition of Abide Therapeutics Inc. will provide H. Lundbeck A/S with a unique discovery platform and a lead compound in an exploratory phase IIa program for Tourette’s syndrome.
FDA approves Roche’s Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
The U.S. Food and Drug Administration approved Roche’s Kadcyla (trastuzumab emtansine) for adjuvant treatment of people with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and Herceptin (trastuzumab)-based treatment.